Therapure Biopharma Inc. and LFB Biotechnologies announce a development services contract for a new therapeutic protein- Published on 04/18/2009
Therapure will apply its expertise to the development of an innovative plasma protein resulting from LFB’s research
TORONTO, CANADA and LES ULIS, FRANCE: [Wednesday, February 18, 2009]Thomas Wellner, President and CEO of Therapure BioPharma Inc. and Christian Béchon, President and CEO of LFB S.A. announce that a development services contract has been concluded between Therapure Biopharma Inc. and LFB Biotechnologies, a subsidiary of LFB SA, for the development of a manufacturing method for an innovative plasma therapeutic protein.
Therapure will apply its experience and knowledge in therapeutic protein development to develop a manufacturing process to enable the large scale production of this important biologic for clinical trials. The project, which is being jointly managed by research and development teams from the two companies, is expected to yield a novel treatment for a serious illness which currently has limited treatment options.
“We are pleased that LFB Biotechnologies, a major European player in the therapeutic protein field, has selected Therapure Biopharma for this important work,” said Thomas Wellner. “Our development team has extensive knowledge in the area of plasma proteins purification and manufacturing methods and we have already achieved some key milestones in this project.” “We have a strong expertise in the development and manufacture of plasma-derived medicinal products and an important R&D portfolio. We have chosen to identify partners with complementary knowledge and the skills to help us to advance some of our products,” said Bernard Pelletier, strategic development program director. “We have recognized the strong technical capabilities of Therapure Biopharma in this area and we are pleased with the progress of the project to date.”
About Therapure Biopharma
Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies, and packages therapeutic proteins. Therapure Biopharma is also a specialist in therapies derived from hemoglobin, a blood protein. As a contract development and manufacturing organization (CDMO) Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market.
For more information, please visit:
LFB is a pharmaceutical group and the first French company in the biotech field. LFB is the fifth largest pharmaceutical company in plasma-derived medicinal products in the world, and the third largest laboratory supplying drugs to hospitals in France. LFB commercializes a wide range of 19 plasma-derived medicinal products, addressing more than 80 pathologies in three therapeutic fields: Immunology, Hemostasis, and Intensive Care. Each year, 500,000 patients are treated with LFB's products for chronic pathologies or for emergency cases. In the biotechnology field, LFB develops monoclonal antibodies and a line of therapeutic proteins through transgenic technology with GTC Therapeutics.
For more information, please visit www.lfb.fr